Liverpool Trust to use AI to help doctors make treatment decisions

Royal Liverpool and Broadgreen University Hospitals NHS Trust has announced it is working with a UK artificial intelligence (AI) health company to improve clinical decision making and to reduce the risk of heart attacks.

The Global Digital Exemplar will use technology from healthcare firm Deontics to improve the treatment for patients who have had a heart attack. Doctors on the Trust’s acute cardiac unit (ACU) will be able to access AI-driven, evidence-based clinical treatment recommendations that are tailored to patients’ needs.

Deontics’ recommendations will include the appropriate guidelines from NICE and other regulatory bodies to help doctors avoid medication that could increase risks of bleeding and recurrent heart attack. The company uses cognitive computing technology and advanced healthcare-specific logic to help doctors navigate clinical decisions. Using the technology, doctors can make treatment decisions that are informed by relevant standards and guidelines such as those issued by NICE.

The collaboration is expected to produce greater clinical compliance with standards, improve care quality, enhancing patient outcomes and reducing hospital stays.

Liverpool chief clinical information officer (CCIO) Mike Fisher, said: “Some of our most frail and elderly patients with acute coronary syndrome are getting some of our most powerful drugs.

“Using AI-technology means we should reduce the potential for overprescribing such drugs for patients at lower levels of risk. Instead of giving some patients the maximum treatment, we can make sure patients are given the most appropriate treatment.”

Deontics will be used on the Trusts’ ACU over summer and will initially only be linked to the electronic notes system. There is an aim to integrate Deontics with other clinical systems, such as the upcoming electronic patient record system.

“Deontics is one of the smartest decision support systems out there,” Fisher added. “It has been used to individually recommend different chemotherapy regimes based on complex research. No other system can do this. It is a very interesting firm, and we are hopeful for a continued relationship.”

Guy Wood-Gush, CEO of Deontics, said: “It is very exciting to be working with the Trust on realising the possibilities of using AI to enhance clinical treatment decisions using Deontics technology. We have spent many years working with clinicians to develop a platform that fits with their needs and workflow. We have shown how our healthcare AI technology can increase patient safety, reduce unnecessary clinical variation, and deliver high quality, cost-effective care and we look forward to bringing these benefits to patients in Liverpool.”

 

 



'Liverpool Trust to use AI to help doctors make treatment decisions' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

© 2018 Rapid Life Sciences Ltd, a Rapid News Communications Group Company. All Rights Reserved.

Privacy policy

Terms and conditions